Mark Olfson

Mark Olfson

Auto-generated profile, based on publicly available information

Mark Olfson

College of Physicians and Surgeons, Columbia University and New York State Psychiatric Institute, New York, New York

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2015 in JAMA Psychiatry
Verified
Journal Article
Open access
PDF file
MOMark Olfson
Mark Olfson
TGTobias Gerhard
Tobias Gerhard
CHCecilia Huang
Cecilia Huang
SCStephen Crystal
Stephen Crystal
TST. Scott Stroup
T. Scott Stroup
Adults with schizophrenia are at markedly increased risk of premature death.1,2 Despite elevated rates of suicide and other unnatural causes of death, most of the excess mortality has been attributed to cardiovascular disease, respiratory disease, and other natural causes.3 One analysis from the United Kingdom found that suicide, homicide, and accidental deaths collectively accounted for 21 of 164 schizophrenia deaths.4 Accurate characterizations of premature mortality patterns are important to inform clinical and policy initiatives to improve services and reduce preventable deaths in this patient population.

1 August 2009 in Archives of General Psychiatry
Verified
Journal Article
Closed access
PDF file
MOMark Olfson
Mark Olfson
SMSteven C. Marcus
Steven C. Marcus
Research from JAMA Psychiatry — National Patterns in Antidepressant Medication Treatment

1 September 2007 in Archives of General Psychiatry
Verified
Journal Article
Open access
PDF file
CMCarmen Moreno
Carmen Moreno
GLGonzalo Laje
Gonzalo Laje
CBCarlos Blanco
Carlos Blanco
HJHuiping Jiang
Huiping Jiang
ASAndrew B. Schmidt
Andrew B. Schmidt
MOMark Olfson
Mark Olfson
Accumulating evidence suggests that there has been a recent increase in the clinical diagnosis of bipolar disorder among young people.1,2 Between 1995 and 2000, the proportion of youth in a large database of privately insured patients who received outpatient treatment for bipolar disorder increased by 67%2 while the proportion who received inpatient treatment for bipolar disorder increased by 74%.1 Recent reports3-5 further indicate that children and adolescents commonly receive pharmacological treatments for bipolar disorder. However, 1 recent study6 suggests that children and adolescents diagnosed with bipolar disorder are somewhat less likely than their adult counterparts to be prescribed mood stabilizers. The extent to which there has been a recent national increase in the outpatient diagnosis of childhood bipolar disorder and the pattern of its pharmacological treatment remain unknown.

1 June 2006 in Archives of General Psychiatry
Verified
Journal Article
Open access
PDF file
MOMark Olfson
Mark Olfson
CBCarlos Blanco
Carlos Blanco
LLLinxu Liu
Linxu Liu
CMCarmen Moreno
Carmen Moreno
GLGonzalo Laje
Gonzalo Laje
Studies1-3 of privately and publicly insured populations indicate recent growth in the treatment of young people with antipsychotic drugs. In a large privately insured prescription database, for example, treatment of youth younger than 18 years with antipsychotic medications increased from 0.32% in 1997 to 0.50% in 2000.1 In Texas, the number of child and adolescent Medicaid enrollees prescribed second-generation antipsychotic medications increased 494% between 1996 and 2000, and the number prescribed first-generation antipsychotic medications increased 160% during that period.2 Similar increases in youth antipsychotic treatment have been reported among the Tennessee Medicaid population.3

1 January 2014 in JAMA Psychiatry
Verified
Journal Article
Open access
PDF file
MOMark Olfson
Mark Olfson
CBCarlos Blanco
Carlos Blanco
SWShuai Wang
Shuai Wang
GLGonzalo Laje
Gonzalo Laje
CCChristoph U. Correll
Christoph U. Correll
Over the last several years, a number of important changes have occurred in the mental health care of children and adolescents in the United States.1-3 Perhaps most importantly, there has been an increased clinical emphasis on pharmacological management.4 This emphasis has been supported by large randomized controlled trials of stimulants for attention-deficit/hyperactivity disorder (ADHD),5 antipsychotics for bipolar mania6 and behavioral problems associated with autism,7 and antidepressants for major depressive disorder8 and several anxiety disorders.9 Advances in pharmacological management, alongside development of evidence-based psychotherapies for common child and adolescent psychiatric disorders,10 have been incorporated into disorder-specific clinical practice guidelines.11-14

1 January 2006 in American Journal of Psychiatry
Verified
Journal Article
Closed access
PDF file
MOMark Olfson
Mark Olfson
SMSteven C. Marcus
Steven C. Marcus
MTMichael Tedeschi
Michael Tedeschi
GWGeorge J. Wan
George J. Wan